Gigaceuticals Tech Files IPO Prospectus: AI-Driven Drug Discovery Targeting Age-Related Metabolic Diseases

Jun 22, 2024 07:54 CST Updated 07:54

GigaCeuticals

AI Drug Discovery Company

GigaCeuticals(GigaCeuticals Tech) is an AI-driven new drug research and development company that was established in 2018 at the Zhongguancun Life Science Park and received angel investments from InnoAngel and ZhenCloud Venture Capital.

The efficacy prediction system (DLEPS, LingSu system) developed by the company, which is based on deep learning and genetic fingerprints, has achieved significant results and has been published in *Nature Biotechnology*. The overall prediction accuracy of the system is about 60%, and multiple efficient compounds have been confirmed, including those for weight loss, uric acid reduction, and treatment of non-alcoholic steatohepatitis.

Estimated reading time: 5 minutes

GigaCeuticals' core technology is the development of the world's leading efficacy prediction system based on deep learning and gene fingerprint (DLEPS, LingSu System)., this system can efficiently discover small-molecule compounds and innovative targets for treating diseases through disease markers. Compared with traditional drug development, GigaCeuticals' AI technology can significantly shorten the drug discovery time, reduce R&D costs, increase success rates, and address complex systemic disease areas where traditional approaches are not applicable.

Dr. Zhengwei Xie, founder of GigaCeuticals, once stated in an interview, "Our goal is to develop drugs that extend lifespan, and the Lingsu system is the key tool to achieve this goal because the field of aging intervention lacks clear targets."

Due to the extensive accumulation of candidate small molecules in the field of anti-aging, Dr. Zhengwei Xie established the skincare brand YASI in 2023. Leveraging the Lingsu system, the company can rapidly discover active natural products and develop highly efficient compound formulations.

In 2024, GigaCeuticals and listed company Qianyuan Pharmaceutical (300254) established a joint venture to advance the development of drug pipelines. "We are also collaborating with world-leading skincare companies to jointly promote the development of functional skincare products," said Dr. Zhengwei Xie.

Currently, the core technology platforms owned by GigaCeuticals mainly include the following aspects:

1. LingSu System (DLEPS):This is a drug efficacy prediction system developed by GigaCeuticals based on gene fingerprints and deep learning. Unlike traditional drug discovery methods that rely on known targets, the LingSu system can efficiently discover small-molecule compounds for treating diseases directly through disease markers. The system can accurately predict changes in gene expression profiles after small-molecule treatment of cells or animals, expanding the applicable molecular space to hundreds of millions.

2. Target prediction system, proprietary high-quality small molecule library, small molecule generation system for specific diseases, ADMET prediction system, drug/small molecule/natural product combination synergy prediction system.

3. 8 Disease/Skin Models:GigaCeuticals has established 8 disease models and predictive gene marker sets, and is developing 5 new disease models, covering fields such as weight loss, hyperuricemia & gout, life extension, non-alcoholic steatohepatitis (NASH), and tendon healing.

4. Cloud Computing Platforms and Drug Design Software:GigaCeuticals is enhancing the development of its cloud computing platform to support the computational needs of drug research and development. The drug design software adopts a server/client architecture, with the client being compatible with multiple platforms including Linux, Windows, and Mac OS.

5. Innovative R&D Laboratory:GigaCeuticals also has an innovative R&D laboratory for experimental research and validation of drugs. These technical platforms together form GigaCeuticals' core competitiveness in the AI-driven drug discovery field. Through these platforms, GigaCeuticals is able to conduct drug discovery and development more efficiently and accurately, accelerating the launch of new drugs.

Dr. Xie Zhengwei said, "Our goal is to leverage cutting-edge technologies such as artificial intelligence and big data to accelerate the new drug development process,To provide patients/people with anti-aging needs with more effective treatment solutions。In the future, the company willContinue to advance the existing drug development pipeline, especially forCompound Development for Weight Loss, Hyperuricemia & Gout, Life Extension, Non-Alcoholic Steatohepatitis (NASH), Tendon Healing, etc.; Secondly, technological iteration: continuously optimizing and upgrading the drug efficacy prediction system (DLEPS, LingSu system) based on deep learning and gene fingerprinting to improve prediction accuracy and R&D efficiency.”

GigaCeuticals is located in the Peking University Medical Park within the Zhongguan Village Life Science Park, another company that has garnered significant external attention.Shenji ChanghuaAlso located here.Shenji ChanghuaIt is a biopharmaceutical company focused on gene therapy for neurological disorders. The core pipeline stems from over a decade of fundamental research achievements in neuroscience from Professor Yichang Jia's laboratory at the School of Medicine, Tsinghua University.

Currently, the first research pipeline SNUG01 for amyotrophic lateral sclerosis developed by Shenchanghua has initiated an investigator-initiated clinical study (IIT) at Peking University Third Hospital. The first compassionate use patient has been on the medication for a full year, and the patient's disease progression has stabilized.Click here for details）。

Recently,Shenji Changhua has collaborated with Mr. Cai Lei, a well-known ALS fighter and former Vice President of JD Group, to establish a joint laboratory., accelerating drug development for Amyotrophic Lateral Sclerosis (ALS, commonly known as Lou Gehrig's disease). This collaboration marks an important step for both parties in the field of neurological disease treatment, contributing to tackling this global challenge.

Pharmaceuticals and HealthThe flower of industrial innovation and development is "vibrantly blooming" in Life Science Park. In the future,Zhangjiang Life Science Park will accelerate the transformation of scientific and technological achievements into real productive forces by relying on the park's first-class research capabilities and complete industrial chain, fostering an innovative breeding ground for双创主体, and building a "Life Valley" with globally leading standards.